Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring of neuromuscular blockade after reversal with neostigmine
2019-000561-20Phase 4Active
- Sponsor
- Tampere University Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of neostigmine methylsulfate + glycopyrronium bromide in neuromuscular block (NMB), sponsored by Tampere University Hospital. Primary endpoint: Incidence of reappearance of neuromuscular block. Started Feb 2020; status: active.
02
Drugs
neostigmine methylsulfate + glycopyrronium bromide
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2019-000561-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000561-20.